Efficiency and safety of silodosin for treatment of lower urinary tract symptoms, associated of benign prostatic hyperplasia
- Authors: Krivoborodov G.G1, Tur E.I2
-
Affiliations:
- N.I. Pirogov RNRMU of Minzdrav of Russia
- University Clinic Mater Domini Catanzaro
- Issue: No 2 (2019)
- Pages: 67-72
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/322089
- DOI: https://doi.org/10.18565/urology.2019.2.67-72
- ID: 322089
Cite item
Open Access
Access granted
Abstract
Benign prostatic hyperplasia commonly is the most common cause of bladder outlet obstruction and can result in storage and micturition symptoms in men older than 40 years. Nowadays the a1-adrenoreceptor antagonists are the first-line drug for treatment of the lower urinary tract symptoms (LUTS). However, a1-adrenoreceptors are known to be present in other tissues and this fact could be a reason of potential risk of adverse events, associated with changes in peripheral vascular tone, such as orthostatic hypotension, syncopal states, dizziness, etc., especially in patients of advanced age, and those affected by cardiovascular diseases and taking essential drugs. A highly selective a-adrenergic blocker silodosin is characterized by a lower rate of mentioned adverse events, comparable with placebo. Silodosin is also highly effective in treating of both types of LUTS in these patients, both as monotherapy and in combination with other drugs. A detailed analysis of clinical data confirming the high efficacy and safety of silodosin is presented in this review of the literature.
Full Text
About the authors
G. G Krivoborodov
N.I. Pirogov RNRMU of Minzdrav of Russia
Email: Dr.krivoborodov@yandex.ru
Department of Urology and Andrology
E. I Tur
University Clinic Mater Domini CatanzaroPh.D., urologist, resident
References
- Martin S.A., Haren M.T., Marshall V.R. et al. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J. Urol. 2011. 29: 179.
- Societe Internationale d’Urologie (SIU), Lower Urinary Tract Symptoms (LUTS): An International Consultation on Male LUTS., C. Chapple & P. Abrams, Editors. 2013.
- Kupelian V., Wei J.T., O’Leary M.P. et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med, 2006. 166: 2381.
- Agarwal A., Eryuzlu L.N., Cartwright R. et al. What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women. Eur Urol. 2014. 65: 1211.
- De Ridder D., Roumeguere T., Kaufman L. Urgency and other lower urinary tract symptoms in men aged>40 years: a Belgian epidemiological survey using the ICIQ-MLUTS questionnaire. Int J. Clin Pract. 2015. 69: 358.
- Kogan M.I., Zachoval R., Ozyurt C. et al. Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr Med Res Opin. 2014. 30: 2119.
- Taub D.A., Wei J.T. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep. 2006;7:272.
- Abrams P., Cardozo L., Fall M. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn. 2002;21:167.
- McVary K.T., Roehrborn C.G., Avins A.L. et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J. Urol. 2011;185:1793- 1803.
- Gratzke C., Bachmann A., Descazeaud A. et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67:1099-1109.
- Michel M.C., Vrydag W. Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J. Pharmacol. 2006;147(Suppl 2):S88.
- Matsukawa Y., Gotoh M., Komatsu T. et al. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study. J. Urol. 2013;189:S117-121.
- Fusco F., Creta M., Longo N., et al. Silodosin 8 mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study. BMC Urol. 2018;18:12.
- Fusco F., Palmieri A., Ficarra V. et al. a1-Blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol. 2016;69:1091-1101.
- Chapple C.R., Montorsi F., Tammela T.L. et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, doubleblind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59:342-352.
- Kawabe K., Yoshida M., Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, doubleblind study in Japanese men. BJU Int. 2006;98:1019-1024.
- Matsukawa Y., Takai S., Funahashi Y. et al. Effects of withdrawing a1-blocker from combination therapy with a1-blocker and 5a-reductase inhibitor in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective and comparative trial using urodynamics. J. Urol. 2017;198:905-912.
- Matsukawa Y., Takai S., Funahashi Y. et al. Long-term efficacy of a combination therapy with an anticholinergic agent and an a1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourol Urodyn. 2017;36:748-754.
- Novara G., Chapple C.R., Montorsi F. A pooled analysis of individual patient data from registrational trials of silodosin in the treatment of non-neurogenic male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). BJU Int. 2014;114:427-433.
- Marks L.S., Gittelman M.C., Hill L.A. et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009;181:2634-2640.
- Nickel J.C., Sander S., Moon T.D. A meta-analysis of the vascular-related safety profile and efficacy of a-adrenergic blockers for symptoms related to benign prostatic hyperplasia. IntJClinPract 2008; 62:1547-1559.
- Wu Y.J., Dong Q., Liu L.R., Wei Q. A meta-analysis of efficacy and safety of the new a (1A)-adrenoceptor-selective antagonist silodosin for treating lower urinary tract symptoms associated with BPH. Prostate Cancer Prostatic Dis 2013;16:79-84.
- Novara G, Tubaro A., Sanseverino R. et al. Systematic review and metaanalysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol. 2013;31:997-1008.
- Villa L., Capogrosspo P., Capitanio U. et al. Silodosin: an update of efficacy and clinical indications in urology. Springer Healthcare Ltd., part of Springer Nature 2018. 2019 Jan;36(1).
Supplementary files
